tstanding - basic 16,535 11,271 16,336 11,223
Dilutive effect of common equivalent
shares 1,219 1,501 1,280 1,505
Pro forma weighted average shares of
common stock outstanding - diluted 17,754 12,772 17,616 12,728
Pro forma net income per share:
Basic $0.93 $0.32 $1.59 $0.77
Diluted $0.87 $0.28 $1.48 $0.68
(1) As a result of the conversion of the Company's preferred stock into
11,032 shares of common stock upon completion of the Company's initial
public offering in November 2007, there is a lack of comparability in
the basic and diluted net income per share amounts for the periods
presented above.
'/>"/>SOURCE Genoptix, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related medicine news :1.
Genoptix, Inc. Announces Pricing for Initial Public Offering2.
Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 20083.
Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 20074.
Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock5.
Genoptix Announces Pricing of Secondary Public Offering6.
Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference7.
Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference8.
Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record9.
Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference10.
Genoptix Reports Strong Financial Results for First Quarter 200811.
Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008